
Aerpio Pharmaceuticals, Inc. ARPO
Aerpio Pharmaceuticals, Inc. General and Administrative Expenses 2011-2026 | ARPO
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Aerpio Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 8.76 M | 9.76 M | 13.5 M | 9.24 M | 29.5 K | 23 K | 22.8 K | 22.4 K | 23.6 K | 20.5 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 13.5 M | 20.5 K | 4.14 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | ||
|
ADMA Biologics
ADMA
|
91.6 M | $ 15.57 | -5.89 % | $ 3.71 B | ||
|
AgeX Therapeutics
AGE
|
9.33 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
AbCellera Biologics
ABCL
|
83.2 M | $ 3.58 | -1.38 % | $ 1.07 B | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Anika Therapeutics
ANIK
|
95.8 M | $ 14.19 | -1.18 % | $ 208 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
Aptorum Group Limited
APM
|
5.41 M | $ 0.82 | -0.73 % | $ 4.47 M | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
550 M | $ 20.24 | 1.91 % | $ 2.55 B | ||
|
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | ||
|
ANI Pharmaceuticals
ANIP
|
250 M | $ 75.6 | -1.22 % | $ 1.46 B | ||
|
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | ||
|
Autolus Therapeutics plc
AUTL
|
46.7 M | $ 1.5 | -8.28 % | $ 383 M | ||
|
Aravive
ARAV
|
13 M | - | -13.39 % | $ 1.45 M | ||
|
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
Athersys
ATHX
|
20.1 M | - | 3.77 % | $ 22.4 M | ||
|
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | ||
|
AVEO Pharmaceuticals
AVEO
|
60.8 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
63.3 M | $ 159.87 | -2.57 % | $ 7.95 B | ||
|
BridgeBio Pharma
BBIO
|
531 M | $ 65.73 | -1.22 % | $ 12.6 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
7.04 M | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
5.72 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | ||
|
Equillium
EQ
|
13.6 M | $ 1.79 | 2.29 % | $ 62.2 M | ||
|
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | ||
|
Bellerophon Therapeutics
BLPH
|
6.02 M | - | -74.18 % | $ 955 K | ||
|
BioLineRx Ltd.
BLRX
|
4.31 M | $ 2.72 | -3.31 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
1.15 B | $ 60.54 | 0.18 % | $ 11.6 B | ||
|
Burford Capital Limited
BUR
|
99.3 M | $ 8.26 | -1.31 % | $ 1.36 B | ||
|
Cabaletta Bio
CABA
|
19.2 M | $ 3.2 | -6.71 % | $ 3.74 M | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
78.7 M | $ 2.93 | -8.44 % | $ 1.05 M | ||
|
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | ||
|
Capricor Therapeutics
CAPR
|
12.8 M | $ 25.74 | 0.94 % | $ 689 M |